Bone and Joint Infection Market to 2016 - Medical Imaging and PCR Methods to Facilitate Early Diagnosis and Treatment - GBI Research Reports

Bone and Joint Infection Market to 2016 - Medical Imaging and PCR Methods to Facilitate Early Diagnosis and Treatment

Bone and Joint Infection Market to 2016 - Medical Imaging and PCR Methods to Facilitate Early Diagnosis and Treatment - GBI Research Reports
Bone and Joint Infection Market to 2016 - Medical Imaging and PCR Methods to Facilitate Early Diagnosis and Treatment
Published Feb 10, 2011
121 pages — Published Feb 10, 2011
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

GBI Research, the leading business intelligence provider, has released its latest research Bone and Joint Infection Market to 2016- Medical Imaging and PCR methods to Facilitate Early Diagnosis and Treatment, which provides insights into bone and joint infections market sales and price forecasts until 2016. The report also examines the global bone and joint infections therapies treatment usage patterns. In addition, the geographical distribution of bone and joint infections therapies across the US, the top five countries in the European region and Japan are also provided in the report. The report provides an in-depth analysis of the top three bone and joint infections market therapeutic indications, which are prosthetic joint infection, osteomyelitis and septic arthritis. Furthermore, it also includes the market forecasts and treatment usage patterns of these these therapeutic indications. Finally, the key trend analysis on Mergers and Acquisitions (M&As) and licensing agreements involving bone and joint infections therapies is also presented.

In-depth analysis of the report is based on propriety databases, primary and secondary research and in-house analysis by the GBI Research team of experts.

GBI Research analysis showed that the global bone and joint infections market was estimated at $0.7 billion in 2009, with a year-on-year growth rate of 6.4% between 2001 and 2009. GBI Research forecasts that the market will grow at a Compound Annual Growth Rate (CAGR) of 8.1% between 2009 and 2016 to record a sales value of $1.2 billion. The patent expiry of two of the branded drugs by 2016 is expected to make way for the entry of generics.

Many of the major pharmaceutical companies such as GlaxoSmithKline, Hoffman-La Roche, Ranbaxy, Bayer AG, Teva Pharmaceuticals, Eli Lilly, Pfizer, Hospira, Leo pharma A/S, App pharmaceuticals and Abbott are either entering or expanding into the market. They are collaborating with or acquiring small and medium-sized enterprises (SME) biotechnology companies. The main factor that is driving the big pharmaceutical companies towards the bone and joint infections therapeutics market is the increasing market for infectious diseases mainly indications related to infections caused due to staphylococcus species. As staphylococcus aureus is one of the major causative organisms for infectious diseases. Bone and joint infections is one of the most common infectious diseases.

Scope

- Data and analysis on the bone and joint infections market in the leading geographies of the world the US, the UK, Germany, France, Italy, Spain, and Japan.
- Annualized market data for the bone and joint infections market from 2001 to 2009, with forecasts to 2016.
- Market data on the geographical landscape and therapeutic landscape, including market size, market share, annual cost of therapy and treatment usage patterns such as disease population, treatment seeking population, diagnosis population and prescription population.
- Key drivers and restraints that have had a significant impact on the market.
- The top companies benchmarking in the bone and joint infections therapeutics market The key companies studied in this report are GlaxoSmithKline, Hoffman-La Roche, Ranbaxy, Bayer AG, Teva Pharmaceuticals, Eli Lilly, Pfizer, Hospira, Leo pharma A/S, App pharmaceuticals and Abbott.
- Key M&A activities and Licensing Agreements that took place in 2008 and 2009 in the bone and joint infections market.

Reasons to buy

The report will assist business development and marketing executives to strategize their product launches, by allowing them to -
- Build effective strategies to launch their pipeline products by identifying potential geographies.
- Exploit in-licensing and out-licensing

  
Source:
Document ID
GBIHC063MR
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents37
  List of Tables53
  List of Figures82
Bone and Joint Infecmtion Market to 2016: Introduction101
  GBI Research Report Guidance101
Bone and Joint Infection Market to 2016: Market Overview119
  Introduction111
  Revenue Forecasts for the Global Bone and Joint Infection Market111
    Revenue112
    Annual Cost of Treatment (ACT)131
    Treatment Usage Patterns142
      Diseased Population161
      Treatment Seeking Population171
      Diagnosis Population181
      Prescription Population191
Bone and Joint Infection Market to 2016: Geographical Landscape2025
  Revenue Analysis by Geography202
  The US221
    Revenue221
    Annual Cost of Treatment (ACT)231
    Treatment Usage Patterns241
      Diseased Population251
      Treatment Seeking Population261
      Diagnosed Population271
      Prescription Population281
  Top Five Countries in Europe291
    Revenue291
    Annual Cost of Treatment (ACT)301
    Treatment Usage Patterns312
      Diseased Population331
      Treatment Seeking Population341
      Diagnosed Population351
      Prescription Population361
  Japan371
    Revenue371
    Annual Cost of Treatment (ACT)381
    Treatment Usage Patterns392
      Diseased Population411
      Treatment Seeking Population421
      Diagnosed Population431
      Prescription Population441
Bone and Joint Infection Market to 2016: Therapeutic Landscape4531
  Prosthetic Joint Infections Therapeutics Market451
    Introduction451
    Revenue461
    Annual Cost of Treatment471
    Treatment Usage Patterns482
      Diseased Population501
      Treatment Seeking Population511
      Diagnosed Population521
      Prescription Population531
    Drivers and Barriers for the Prosthetic Joint Infections Therapeutics Market541
    Drivers for the Prosthetic Joint Infections Therapeutics Market541
      Increasing Use of High Cost Antibiotics541
      Increase in Joint Replacement Therapies for Arthritis and Joint Infections541
      Increasing treatment seeking population541
    Barriers for the Prosthetic Joint Infections Therapeutics Market551
      Availability of Alternative Options551
    Opportunity and Unmet Need551
  Osteomyelitis Therapeutics Market551
    Introduction551
    Revenue561
    Annual Cost of Treatment (ACT)571
    Treatment Usage Patterns582
      Diseased Population601
      Treatment Seeking Population611
      Diagnosed Population621
      Prescription Population631
    Drivers and Barriers for the Osteomyelitis Therapeutics Market641
    Drivers for the Osteomyelitis Therapeutics Market641
      Introduction of novel drug therapies641
      Diagnosis Rate641
    Barriers for the Osteomyelitis Therapeutics Market651
      Lower Patient Affordability651
      Low Treatment Seeking Rate651
    Opportunity and Unmet Need651
  Septic Arthritis Therapeutics Market651
    Introduction651
    Revenue661
    Annual Cost of Treatment (ACT)671
    Treatment Usage Patterns682
      Diseased Population701
      Treatment Seeking Population711
      Diagnosed Population721
      Prescription Population731
    Drivers and Barriers for the Septic Arthritis Therapeutics Market741
    Drivers for the Septic Arthritis Therapeutics Market741
      Availability of alternative options741
      Increasing treatment seeking rate741
    Barriers for the Septic Arthritis Therapeutics market751
      Improper diagnosis of septic arthritis751
    Opportunity and Unmet Need751
Bone and Joint Infection Market to 2016: Pipeline Analysis7613
  Introduction761
    Research and Development Pipeline-Bone and Joint Infection765
  Profiles of Key Late Stage Drugs in the Bone and Joint Infection Market811
    Pagibaximab811
      Overview811
      Efficacy811
      Safety811
      Clinical Study Details811
    TAKSTA811
      Overview811
      Efficacy811
      Safety811
      Clinical Study Details811
    V710821
      Overview821
      Efficacy821
      Safety Profile821
      Clinical Study Details821
    Ceftobiprole821
      Overview821
      Efficacy831
      Safety Profile831
      Clinical Study Details831
    Teflaro841
      Overview841
      Efficacy841
      Safety Profile851
      Clinical Study Details851
    Torezolid861
      Overview861
      Efficacy861
      Safety Profile861
      Clinical Study Details871
    Rotarix + Infanrix + Pediarix + GSK 208108 + Prevnar 13871
      Overview871
      Safety Profile and Efficacy881
      Clinical Study Details881
Bone and Joint Infection Market to 2016: Competitive Landscape8922
  Overview891
  Competitive Profiling891
    Sandoz GmbH891
      Company Overview891
      Marketed Products892
    GlaxoSmithKline911
      Company Overview911
      Marketed Products921
    F. Hoffmann-La Roche Ltd.931
      Company Overview931
      Marketed Products941
    Ranbaxy941
      Company Overview941
      Marketed Products951
    Bayer AG961
      Company Overview961
      Marketed Products972
    Teva Pharmaceutical Industries Limited991
      Company Overview991
      Marketed Products993
    Eli Lilly and Company1021
      Company Overview1021
      Marketed Products1022
    Pfizer Inc.1041
      Company Overview1041
      Marketed Products1042
    Hospira, Inc.1061
      Company Overview1061
      Marketed Products1061
    LEO Pharma A/S1071
      Company Overview1071
      Marketed Products1081
    APP Pharmaceuticals, Inc.1081
      Company Overview1081
      Marketed Products1091
    Abbott Laboratories1091
      Company Overview1091
      Marketed Products1092
Bone and Joint Infection Market to 2016: M&A Landscape1115
  Global Bone and Joint Infection Market1111
    Overview: Deals by Type1111
  Mergers and Acquisitions1121
    Overview1121
    Durata Therapeutics Acquires Vicuron Pharmaceuticals1121
    Aptuit Acquires Medicines Research Centre from GlaxoSmithKline1121
    Hospira Acquires Pliva1131
  Licensing Agreements1141
    GlaxoSmithKline (GSK) and Isis Pharmaceuticals1141
    Sanofi-aventis and Novozymes1141
    Deals by Geography1141
    Deals by Year1151
Bone and Joint Infection Market to 2016: Appendix1166
  Market Definition1161
  Abbreviations1161
  Research Methodology1174
    Coverage1171
    Secondary Research1171
    Forecasting1181
      Epidemiology-based Forecasting1182
    Primary Research1201
    Expert Panels1201
  Contact Us1201
  Disclaimer1211
  Sources1211

Table Of Contents

GBI Research Reports—GBI Research covers worldwide markets and issues, supplies actionable data and forecasts and is driven by industry leaders' insights. GBI Research provides a broad spectrum of reports across the healthcare and energy industries and its online offering is easy to navigate - a comprehensive resource for business information needs.

About the Author


Cite this Report

  
MLA:
GBI Research Reports. "Bone and Joint Infection Market to 2016 - Medical Imaging and PCR Methods to Facilitate Early Diagnosis and Treatment" Feb 10, 2011. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Bone-and-Joint-Infection-Market-to-2016-Medical-Imaging-and-PCR-Methods-to-Facilitate-Early-Diagnosis-and-Treatment-2115-160>
  
APA:
GBI Research Reports. (2011). Bone and Joint Infection Market to 2016 - Medical Imaging and PCR Methods to Facilitate Early Diagnosis and Treatment Feb 10, 2011. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Bone-and-Joint-Infection-Market-to-2016-Medical-Imaging-and-PCR-Methods-to-Facilitate-Early-Diagnosis-and-Treatment-2115-160>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.